DCIS-associated stromal changes, including DCIS regressive changes, often co-occur with DCIS characteristics that are associated with a poor prognosis and/or aggressive phenotype, such as the HER2-positive subtype and high numbers of tumor infiltrating lymphocytes (TILs) [13]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.